As the U.S. stock market continues to reach new heights, with the S&P 500 and Nasdaq hitting record levels amid easing trade tensions and strong corporate earnings, investors are closely monitoring developments in the tech sector, particularly as major companies prepare to release their quarterly results. In this dynamic environment, identifying high-growth tech stocks involves examining those with robust innovation capabilities and adaptability to evolving market trends, which can potentially offer significant opportunities for growth within the ever-changing landscape of technology investments.
Let’s explore several standout options from the results in the screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Verra Mobility Corporation offers smart mobility technology solutions across the United States, Australia, Europe, and Canada with a market cap of approximately $3.98 billion.
Operations: The company generates revenue through three primary segments: Parking Solutions ($81.01 million), Commercial Services ($413.18 million), and Government Solutions ($398.54 million).
Verra Mobility, amidst a challenging market backdrop with a recent drop from the Russell 2000 Dynamic Index, is navigating through significant shifts. The appointment of Stacey Moser as Executive Vice President and General Manager of the Commercial Services business unit could inject fresh strategic insights, given her extensive background in global commercial roles and product management. Financially, Verra’s first quarter results showed a revenue increase to $223.25 million from $209.73 million year-over-year, with net income also rising to $32.34 million from $29.15 million. Despite these gains, the company’s overall annual revenue growth forecast at 6.8% lags behind the U.S market projection of 9%. However, its earnings are expected to surge by 46.8% annually, outpacing general market predictions significantly.
VRRM Revenue and Expenses Breakdown as at Jul 2025
Simply Wall St Growth Rating: ★★★★★☆
Overview: Arcutis Biotherapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of treatments for dermatological diseases, with a market cap of approximately $1.77 billion.
Operations: Arcutis Biotherapeutics generates its revenue primarily from the development and commercialization of treatments for dermatological diseases, amounting to $212.82 million. The company’s focus on this niche market segment is reflected in its business operations and financial performance.
Arcutis Biotherapeutics, with its recent FDA approval for ZORYVE® topical foam 0.3%, is making strides in the treatment of plaque psoriasis, a condition affecting nearly 9 million Americans. This approval underscores the company’s commitment to addressing unmet medical needs through innovative dermatological solutions. Furthermore, Arcutis has demonstrated robust revenue growth at an annual rate of 26.7%, outpacing the broader U.S market’s growth forecast of 9%. The company’s R&D efforts are substantial, as evidenced by their ongoing clinical trials and product development initiatives aimed at expanding treatment options across various age groups and severities of dermatological conditions. These strategic moves could significantly influence future revenue streams and market positioning in specialized healthcare sectors.
ARQT Revenue and Expenses Breakdown as at Jul 2025
Simply Wall St Growth Rating: ★★★★★★
Overview: Lumentum Holdings Inc. is a company that manufactures and sells optical and photonic products across various regions including the Americas, Asia-Pacific, Europe, the Middle East, and Africa with a market capitalization of $7.25 billion.
Operations: Lumentum Holdings generates revenue primarily from its Industrial Tech and Cloud & Networking segments, with the latter contributing $1.24 billion. The company’s market capitalization is approximately $7.25 billion.
Lumentum Holdings has been making significant strides in the high-growth tech sector, particularly with its recent inclusion in various Russell growth indices, signaling robust investor confidence. The company’s focus on advanced laser technologies and 3D sensing solutions, as showcased at the Laser World of Photonics 2025, positions it well within industrial photonics and precision manufacturing—a sector poised for expansion. Despite current unprofitability, Lumentum’s strategic R&D investments are set to foster innovation in consumer electronics and energy storage, with revenue expected to grow by 21.6% annually. Moreover, the company is projected to shift towards profitability with an anticipated earnings growth of 106.24% per year, underpinning its potential rebound in financial health.
LITE Revenue and Expenses Breakdown as at Jul 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include VRRMARQT and LITE.
